Search for content, post, videos

Diamyd Medical receives patent protection in the US and Japan

Ulf Hannelius
The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the company’s oral formulation of the GABA-based study drug Remygen. Remygen is currently in Phase 2 development through the ReGenerate-1 trial in individua
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.